This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Jul;5(7):496.

doi: 10.1016/S2213-8587(17)30179-1.

Sacubitril/valsartan in PARADIGM-HF - Authors' reply

Jelena P Seferovic¹, Brian Claggett¹, Scott D Solomon²; PARADIGM-HF investigators

Affiliations

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston MA, 02115, USA.
² Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston MA, 02115, USA. Electronic address: ssolomon@bwh.harvard.edu.

PMID: 28645439
DOI: 10.1016/S2213-8587(17)30179-1

Comment

Sacubitril/valsartan in PARADIGM-HF - Authors' reply

Jelena P Seferovic et al. Lancet Diabetes Endocrinol. 2017 Jul.

. 2017 Jul;5(7):496.

doi: 10.1016/S2213-8587(17)30179-1.

Authors

Jelena P Seferovic¹, Brian Claggett¹, Scott D Solomon²; PARADIGM-HF investigators

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston MA, 02115, USA.
² Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston MA, 02115, USA. Electronic address: ssolomon@bwh.harvard.edu.

PMID: 28645439
DOI: 10.1016/S2213-8587(17)30179-1

No abstract available

PubMed Disclaimer

Comment on

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Seferovic JP, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6. Epub 2017 Mar 18. Lancet Diabetes Endocrinol. 2017. PMID: 28330649 Free PMC article. Clinical Trial.
Sacubitril/valsartan in PARADIGM-HF.
Guglin M. Guglin M. Lancet Diabetes Endocrinol. 2017 Jul;5(7):494-495. doi: 10.1016/S2213-8587(17)30173-0. Lancet Diabetes Endocrinol. 2017. PMID: 28645436 No abstract available.
Sacubitril/valsartan in PARADIGM-HF.
Flores D, Sabti Z, Kozhuharov N, Mueller C. Flores D, et al. Lancet Diabetes Endocrinol. 2017 Jul;5(7):495. doi: 10.1016/S2213-8587(17)30172-9. Lancet Diabetes Endocrinol. 2017. PMID: 28645437 No abstract available.
Sacubitril/valsartan in PARADIGM-HF.
Vodovar N, Nougué H, Launay JM, Solal AC, Logeart D. Vodovar N, et al. Lancet Diabetes Endocrinol. 2017 Jul;5(7):495-496. doi: 10.1016/S2213-8587(17)30177-8. Lancet Diabetes Endocrinol. 2017. PMID: 28645438 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal